CytoDyn (OTCMKTS:CYDY) Releases Quarterly Earnings Results

CytoDyn (OTCMKTS:CYDY) issued its quarterly earnings data on Tuesday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, reports.

CytoDyn Stock Performance

OTCMKTS:CYDY opened at $0.14 on Friday. CytoDyn has a fifty-two week low of $0.11 and a fifty-two week high of $0.42. The company has a 50 day moving average price of $0.15 and a 200 day moving average price of $0.15. The stock has a market capitalization of $152.04 million, a P/E ratio of -2.87 and a beta of 0.13.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.